Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer

References

• World Health OrganizationGLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 Available from http://globocan.iarc.fr/Pages/fact_sheets_population.aspxAccessed February 19, 2014
   Google Scholar
• Ovarian cancer [webpage on the Internet]Bethesda, MDNational Cancer Institute Available from: http://seer.cancer.gov/statfacts/html/ovary.htmlAccessed February 7, 2014
   Google Scholar
• ShihKKChiDSMaximal cytoreductive effort in epithelial ovarian cancer surgeryJ Gynecol Oncol2010212758020613895
   PubMed Web of Science ®Google Scholar
• McGuireWPHoskinsWJBradyMFCyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancerN Engl J Med19963341167494563
   PubMed Web of Science ®Google Scholar
• KatsumataNYasudaMTakahashiFJapanese Gynecologic Oncology GroupDose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trialLancet200937496981331133819767092
   PubMed Web of Science ®Google Scholar
• VergoteITropéCGAmantFEuropean Organization for Research and Treatment of Cancer–Gynaecological Cancer GroupNCIC Clinical Trials GroupNeoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancerN Engl J Med201036394395320818904
   PubMed Web of Science ®Google Scholar
• ChiDSEisenhauerELLangJWhat is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian cancer (EOC)?Gynecol Oncol200610355956416714056
   PubMed Web of Science ®Google Scholar
• DuthieSJFolic acid deficiency and cancer: mechanisms of DNA instabilityBr Med Bull19995557859210746348
   PubMed Web of Science ®Google Scholar
• UlrichCMFolate and cancer prevention – where to next? CounterpointCancer Epidemiol Biomarkers Prev2008172226223018768487
   PubMed Web of Science ®Google Scholar
• MatherlyLHGoldmanDIMembrane transport of folatesVitam Horm20036640345612852262
   PubMed Web of Science ®Google Scholar
• MatherlyLHHouZDengYHuman reduced folate carrier: translation of basic biology to cancer etiology and therapyCancer Metastasis Rev20072611112817334909
   PubMed Web of Science ®Google Scholar
• AntonyACFolate receptorsAnnu Rev Nutr1996165015218839936
   PubMed Web of Science ®Google Scholar
• LeamonCPLowPSDelivery of macromolecules into living cells: a methods that exploits folate receptor endocytosisProc Natl Acad Sci U S A199188557255762062838
   PubMed Web of Science ®Google Scholar
• WeitmanSDLarkRHConeyLRDistribution of the folate receptor GP38 in normal and malignant cell lines and tissuesCancer Res199252339634011596899
   PubMed Web of Science ®Google Scholar
• SandovalRMKennedyMDLowPSMolitorisBAUptake and trafficking of fluorescence conjugates of folic acid in intact kidney determined using intravital two-photon microscopyAm J Physiol Cell Physiol2004287C517C52615102609
   PubMed Web of Science ®Google Scholar
• WangXShenFFreisheimJHGentryLERatnamMDifferential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolatesBiochem Pharmacol1992449189819011449544
   PubMed Web of Science ®Google Scholar
• ShenFRossJFWangXRatnamMIdentification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificityBiochemistry1994335120912158110752
   PubMed Web of Science ®Google Scholar
• CraneLMArtsHJvan OostenMThe effect of chemotherapy on expression of folate receptor-alpha in ovarian cancerCell Oncol (Dordr)20123591821647742
   PubMed Web of Science ®Google Scholar
• WuMGunningWRatmanMExpression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervixCancer Epidemiol Biomarkers Prev1999877578210498396
   PubMed Web of Science ®Google Scholar
• ChenYLChangMCHuangCYSerous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-responseMol Oncol2012636036922265591
   PubMed Web of Science ®Google Scholar
• DespierreELambrechtsSLeunenKFolate receptor alpha (FRA) expression remains unchanged in epithelial ovarian cancer and endometrial cancer after chemotherapyGynecol Oncol201313019219923558051
   PubMed Web of Science ®Google Scholar
• KalliKRObergALKeeneyGLFolate receptor alpha as a tumor target in epithelial ovarian cancerGynecol Oncol2008108361962618222534
   PubMed Web of Science ®Google Scholar
• SiuMKKongDSChanHYParadoxical impact of two folate receptors, FRα and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcomesPLoS One2012711e4720123144806
   PubMed Web of Science ®Google Scholar
• ToffoliGRussoAGalloAExpression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancerInt J Cancer19987921211269583724
   PubMed Web of Science ®Google Scholar
• LuyckxMLeblancEFilleronTMaximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric StudyInt J Gynecol Cancer20122281337134322964527
   PubMed Web of Science ®Google Scholar
• GuoWJZhangYMZhangLNovel monofunctional platinum (II) complex Mono-Pt induces apoptosis-independent autophagic cell death in human ovarian carcinoma cells, distinct from cisplatinAutophagy20139996100823580233
   PubMed Web of Science ®Google Scholar
• ColomboPEFabbroMTheilletCBibeauFRouanetPRay-CoquardISensitivity and resistance to treatment in the primary management of epithelial ovarian cancerCrit Rev Oncol Hematol Epub September 8, 2013
   Web of Science ®Google Scholar
• MironavaTSimonMRafailovichMHRigasBPlatinum folate nanoparticles toxicity: cancer vs normal cellsToxicol In Vitro20132788288923318730
   PubMed Web of Science ®Google Scholar
• MarkmanMRothmanRHakesTSecond-line platinum therapy in patients with ovarian cancer previously treated with cisplatinJ Clin Oncol1991933893931999708
   PubMed Web of Science ®Google Scholar
• AndrewsPAHowellSBCellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistanceCancer Cells1990235432204382
   PubMed Web of Science ®Google Scholar
• OttoneFMiottiSBottiniCRelationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell linesBr J Cancer199776177829218736
   PubMed Web of Science ®Google Scholar
• TaziYPautierPLearyALhommeCChemotherapy in epithelial ovarian cancerGynecol Obstet Fertil20134110611616 French24094667
   PubMedGoogle Scholar
• LeamonCPLovejoyCDNguyenBPatient selection and targeted treatment in the management of platinum-resistant ovarian cancerPharmgenomics Pers Med2013611312524109193
   PubMedGoogle Scholar
• WaltersCLArendRCArmstrongDKNaumannRWAlvarezRDFolate and folate receptor alpha antagonists mechanism of action in ovarian cancerGynecol Oncol201313149349823863359
   PubMed Web of Science ®Google Scholar
• VlahovIRSanthapuramHKKleindlPJHowardSJStanfordKMLeamonCPDesign and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazideBioorg Med Chem Lett200616195093509616870437
   PubMed Web of Science ®Google Scholar
• ReddyJADortonRWestrickEPreclinical evaluation of EC145, a folate-vinca alkaloid conjugateCancer Res2007674434444217483358
   PubMed Web of Science ®Google Scholar
• LorussoPMEdelmanMJBeverSLPhase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumorsJ Clin Oncol2012304011401623032618
   PubMed Web of Science ®Google Scholar
• LeamonCPReddyJAKleinPJReducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modificationsJ Pharmacol Exp Ther201133633634320978169
   PubMed Web of Science ®Google Scholar
• NaumannRWColemanRLBurgerRAPRECEDENT: a randomized Phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone with platinum-resistant ovarian cancerJ Clin Oncol201331354400440624127448
   PubMed Web of Science ®Google Scholar
• NaumannRWColemanRLManagement strategies for recurrent platinum-resistant ovarian cancerDrugs201171111397141221812505
   PubMed Web of Science ®Google Scholar
• Pujade-LauraineEHilpertFWeberBAURELIA InvestigatorsAURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)ASCO Annual Meeting 2012Chicago, Illinois, USASaturday 2 June 2012J Clin Oncol201230Suppl 18 abstract LBA5002
   Google Scholar
• EbelWRouthierELFoleyBPreclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alphaCancer Immun20077617346028
   PubMedGoogle Scholar
• SpannuthWLynYMerrittWTherapeutic efficacy of folate receptor α blockade with MORAb-003 in ovarian cancerGynecol Oncol2008108135 (abstract 307)
   Web of Science ®Google Scholar
• KonnerJABell-McGuinnKMSabbatiniPFarletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I studyClin Cancer Res201016215288529520855460
   PubMed Web of Science ®Google Scholar
• ArmstrongDKWhiteAJWeilSCPhillipsMColemanRLFarletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancerGynecol Oncol201312945245823474348
   PubMed Web of Science ®Google Scholar
• PR NewswireMorphotek Announces Top-Line Results of a Phase III Study of Farletuzumab in Patients With Relapsed Platinum-Sensitive Epithelial Ovarian Cancer [press release]Exton, PAMorphotek® Inc.2010312 Available from: http://www.prnewswire.com/news-releases/morphotek-announces-top-line-results-of-a-phase-iii-study-of-farletuzumab-in-patients-with-relapsed-platinum-sensitive-epithelial-ovarian-cancer-186384621.htmlAccessed February 20, 2014
   Google Scholar
• Esai Co., LtdEisai announces results of phase III study of anticancer agent farletuzumab in patients with relapsed platinum-sensitive ovarian cancer [press release]Tokyo, JapenEsai Co., Ltd2013111 Available from: http://www.eisai.com/news/news201305.htmlAccessed February 20, 2014
   Google Scholar
• Merck Sharp and Dohme CorpA randomized double-blind phase 3 trial comparing EC145 and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) in combination versus PLD in participants with platinum-resistant ovarian cancer Available from: http://clinicaltrials.gov/ct2/show/NCT01170650. NLM identifier: NCT01170650. Accessed
   Google Scholar
• ToffoliGCernigoiCRussoAGalloABagnoliMBoiocchiMOverexpression of folate binding protein in ovarian cancerInt J Cancer1997741931989133455
   PubMed Web of Science ®Google Scholar
• BagnoliMCanevariSFiginiMA step further in understanding the biology of the folate receptor in ovarian carcinomaGynecol Oncol200388S140S14412586106
   PubMed Web of Science ®Google Scholar
• ParkerNTurkMJWestrickELewisJDLowPSLeamonCPFolate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assayAnal Biochem200533828429315745749
   PubMed Web of Science ®Google Scholar
• KelemenLESellersTAKeeneyGLLingleWLMultivitamin and alcohol intake and folate receptor alpha expression in ovarian cancerCancer Epidemiol Biomarkers Prev20051492168217216172227
   PubMed Web of Science ®Google Scholar
• O’ShannessyDJSomersEBSmaleRFuYSExpression of folate receptor–α (FRA) in gynecologic malignancies and its relationship to the tumor typeInt J Gynecol Pathol2013323256268
   Web of Science ®Google Scholar
• LeamonCPReddyJAHainesBDussaultIVintafolide: a first-in-class small molecule drug conjugate targeting folate receptor-positive tumorsPoster #5502/12
   Google Scholar